Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial
View ORCID ProfileAnne Camille La Flamme, David Abernethy, Dalice Sim, Liz Goode, Michelle Lockhart, David Bourke, Imogen Milner, Toni-Marie Garrill, Purwa Joshi, Eloise Watson, Duncan Smyth, Sean Lance, Bronwen Connor
doi: https://doi.org/10.1101/2020.03.12.20034983
Anne Camille La Flamme
1School of Biological Sciences, Victoria University of Wellington, Wellington New Zealand
2Malaghan Institute of Medical Research, Wellington, New Zealand
PhDDavid Abernethy
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
FRACPDalice Sim
4Biostatistical Consulting Group, University of Otago, Wellington, New Zealand
PhDLiz Goode
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
BNMichelle Lockhart
5Pharmaceuticol Ltd, Auckland, New Zealand
PhDDavid Bourke
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
FRACPImogen Milner
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
RNToni-Marie Garrill
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
Purwa Joshi
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
FRACPEloise Watson
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
RACPDuncan Smyth
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
FRACPSean Lance
3Neurology Department, Wellington Regional Hospital, Wellington, New Zealand
RACPBronwen Connor
6Department of Pharmacology and Clinical Pharmacology, Centre for Brain Research, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand
PhDArticle usage
Posted March 16, 2020.
Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial
Anne Camille La Flamme, David Abernethy, Dalice Sim, Liz Goode, Michelle Lockhart, David Bourke, Imogen Milner, Toni-Marie Garrill, Purwa Joshi, Eloise Watson, Duncan Smyth, Sean Lance, Bronwen Connor
medRxiv 2020.03.12.20034983; doi: https://doi.org/10.1101/2020.03.12.20034983
Safety and acceptability of clozapine and risperidone in progressive multiple sclerosis: a phase 1, randomized, blinded, placebo-controlled trial
Anne Camille La Flamme, David Abernethy, Dalice Sim, Liz Goode, Michelle Lockhart, David Bourke, Imogen Milner, Toni-Marie Garrill, Purwa Joshi, Eloise Watson, Duncan Smyth, Sean Lance, Bronwen Connor
medRxiv 2020.03.12.20034983; doi: https://doi.org/10.1101/2020.03.12.20034983
Subject Area
Subject Areas
- Addiction Medicine (313)
- Allergy and Immunology (616)
- Anesthesia (158)
- Cardiovascular Medicine (2253)
- Dermatology (199)
- Emergency Medicine (368)
- Epidemiology (11542)
- Forensic Medicine (10)
- Gastroenterology (676)
- Genetic and Genomic Medicine (3539)
- Geriatric Medicine (336)
- Health Economics (611)
- Health Informatics (2283)
- Health Policy (909)
- Hematology (333)
- HIV/AIDS (741)
- Medical Education (357)
- Medical Ethics (100)
- Nephrology (385)
- Neurology (3322)
- Nursing (189)
- Nutrition (504)
- Oncology (1747)
- Ophthalmology (521)
- Orthopedics (208)
- Otolaryngology (283)
- Pain Medicine (221)
- Palliative Medicine (66)
- Pathology (434)
- Pediatrics (997)
- Primary Care Research (398)
- Public and Global Health (5966)
- Radiology and Imaging (1213)
- Respiratory Medicine (806)
- Rheumatology (367)
- Sports Medicine (309)
- Surgery (383)
- Toxicology (50)
- Transplantation (169)
- Urology (142)